Acadia Pharmaceuticals shares are trading higher Wednesday after the company won summary judgement in a patent suit. Just then Acadia Surged upto 33% in regards to the news.
Acadia Pharmaceuticals (ACAD) notched a win in a patent battle Wednesday pertaining to its Parkinson's drug, Nuplazid. ACAD stock soared to a four-month high.
ACAD Stock: Cashing In On...
ACAD LONG SET UP, ACAD Gapped down over 25% to a New 52 week low.
Price should bounce and fill in the Gap in the market
ACAD also filled its previous Buy gap from Sep 4th 2019
Title: Buy ACAD (ACADIA Pharmaceuticals)
Asset: Stock
Platform: Robinhood/WeBull/Etrade/ 401k account
Symbol: ACAD
Type: Buy Market Execution / Buy Limit
Time Frame: 1D
Entry Price...
buy ACAD
entry 1 $44.50 & entry 2 $42.50
sl $38.50
tp.1 $50.50 tp.2 $55.50 Tp.3 $60.00 Tp.4 $70.50 Tp.5 $80.00
many products releasing soon
Sector: Health Technology
Industry: Biotechnology
Employees: 503
ACADIA Pharmaceuticals , Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical...
many products releasing soon
Sector: Health Technology
Industry: Biotechnology
Employees: 503
ACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firms product include Nuplazid, which is used for the...
